Trials / Unknown
UnknownNCT02059720
Haplo-SCT vs ASCT With or Without Decitabine in AML CR1
Haplo-mismatch Donor Stem Cell Transplantation (SCT) Versus Autologous SCT Followed or Not by Maintenance Therapy, for Patients With Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 212 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A multicentre, prospective, open-label clinical study, including a randomized controlled study in low or intermediate-risk group patients, and a cohort study of maintenance treatment with decitabine after ASCT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | HSCT | Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved. |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2014-02-11
- Last updated
- 2020-02-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02059720. Inclusion in this directory is not an endorsement.